Studies Differ on Benefits of Aggressive Blood Sugar Control

Related Encyclopedia • Addison's Disease • Alzheimer's Disease • Aneurysms • Angina Pectoris More... Related Healthscout Videos Monitoring Diabetes Patients And Doctors Discuss The I-Port Traditional Insulin Delivery Methods What Is Diabetes More... Related Animations • Alzheimer's Disease Video Animation • Angioplasty • Coronary Bypass Surgery • Diabetes More... Related Drug Information • Accupril • Actonel • Actos • Altace More... Related News Articles • Nutrient-Rich Diet Lowers Risk of Age-Related Eye Disease • Health Tip: Taking a Trip When You Have Diabetes • Years of Heavy Smoking Raises Heart Risks • Chewable Aspirin More Readily Absorbed More...

Page:  << Prev | 1 | 2 | 3

In the study, 10,251 patients with type 2 diabetes received intensive blood sugar control or standard treatment. During the trial, there was a 35 percent higher rate of death from cardiovascular events among patients in the intensive treatment group. However, those in the intensive care group also had a 24 percent lower risk of having a nonfatal heart attack. There was no difference between the groups in the risk for nonfatal stroke or heart failure, the researchers found.

Despite the findings of the ACCORD trial, one diabetes expert doesn't think they apply to most people with type 2 diabetes.

"Early and aggressive blood glucose control remains the optimum treatment approach for people with type 2 diabetes," said Dr. James A. Underberg, a clinical assistant professor of medicine at New York University Medical School.

Text Continues Below

---

Underberg said the results of the trial reflected the patient population in the study -- people with heart problems -- and not the dangers of aggressively lowering blood sugar.

"Data showing that high-risk patients are at greater risk for heart disease are not surprising, and should be considered a non-event for the average patient," Underberg said. "It's important that we don't lose sight of the benefits of lowering blood sugar, including fewer long-term microvascular complications."

"As I've always told my patients with type 2 diabetes, it's important to achieve and maintain your blood sugar goals," he said. "ACCORD hasn't changed any of that. The trial was conducted in a select patient population, which is just not reflective of the majority of the millions of Americans with type 2 diabetes."

More information

To learn more about type 2 diabetes, visit the American Diabetes Association.

Page:  << Prev | 1 | 2 | 3